Atossa Therapeutics announced that a two-week Phase 1 study evaluating the safety of two dose levels of the company's AT-301 nasal spray in healthy volunteers demonstrated that the nasal spray was safe and well tolerated. The company announced in August 2020 that it had received approval for the Phase 1 trial of AT-301, which it is developing as an at-home treatment … [Read more...] about Positive Phase 1 results for Atossa’s AT-301 nasal spray
News
The Year of the Aerosol Scientist
Reflections by Philip Kuehl and Jacob McDonald, Lovelace Biomedical What a year! 2020 was the year when those of us in aerosol science were forced to stop compartmentalizing. It was the year that we could no longer keep our work lives separate from our personal lives – our work spilled over into our personal lives on a daily basis. 2020 was the year that the … [Read more...] about The Year of the Aerosol Scientist
Virpax begins pre-clinical studies of intranasal enkephalin to support IND
Virpax Pharmaceuticals said that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health has begun pre-clinical studies of Virpax's Envelta intranasal enkephalin to support an IND submission. Virpax signed a cooperative research and development agreement with NCATS in August 2020. Envelta is delivered via a single use … [Read more...] about Virpax begins pre-clinical studies of intranasal enkephalin to support IND
Aridis announces planned clinical development of inhaled mAb cocktail for COVID-19
Aridis Pharmaceuticals announced that it is now receiving preclinical support from the NIAID (National Institute of Allergy and Infectious Diseases) and CoVIC (Coronavirus Immunotherapy Consortium) for a nebulized monoclonal antibody cocktail for COVID-19 and that it plans to initiate a Phase 1/2/3 clinical trial in the second half of this year. The company also said … [Read more...] about Aridis announces planned clinical development of inhaled mAb cocktail for COVID-19
Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway
According to Union therapeutics, the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have begun recruiting kidney patients for a clinical trial of Union's UNI91103 intranasal niclosamide for the prevention of COVID-19 in vulnerable patients. The PROTECT-V (PROphylaxis for vulnerable paTiEnts at risk of COVID-19 infecTion) trial is … [Read more...] about Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway
Ryaltris nasal spray approved by Russian Ministry of Health
Glenmark Pharmaceuticals announced that the Ministry of Health of the Russian Federation has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal and perennial allergic rhinitis, and the company expects to launch the nasal spray in Russia in the first quarter of fiscal year 2021-22. Glenmark Pharmaceuticals Senior … [Read more...] about Ryaltris nasal spray approved by Russian Ministry of Health
Microbion gets additional funding from CFF for inhaled pravibismane
According to Microbion Corporation, the company has received up to $1.8 million from the Cystic Fibrosis Foundation to fund toxicology studies to support an IND for the company's pravibismane inhalation suspension for the treatment of lung infections in CF patients. CFF had previously provided a grant worth up to $5.6 million for development of the inhaled … [Read more...] about Microbion gets additional funding from CFF for inhaled pravibismane
TFF Pharmaceuticals says it has formulated a dry powder mAb against Ebola and vaccine against equine encephalitis
TFF Pharmaceuticals said that in vitro testing has confirmed the efficacy of a monoclonal antibody against Ebolavirus Zaire and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against Venezuelan equine encephalitis virus formulated using the company's thin film freezing technology. According to TFF, the in vitro studies demonstrated that both the … [Read more...] about TFF Pharmaceuticals says it has formulated a dry powder mAb against Ebola and vaccine against equine encephalitis
Insmed says Phase 1 study of treprostinil palmitil inhalation powder supports once-daily dosing
Insmed Incorporated has announced data from a Phase 1 study of its treprostinil palmitil inhalation powder (TPIP) in healthy volunteers demonstrated that TPIP was generally safe and well tolerated and had a lower Cmax and longer half-life than Tyvaso. The study enrolled 42 subjects and evaluated doses as high as 225 µg for a repeated dose and 675 µg for a single … [Read more...] about Insmed says Phase 1 study of treprostinil palmitil inhalation powder supports once-daily dosing
Seelos repurchases royalties on any future sales of SLS-002 intranasal racemic ketamine
Seelos Therapeuticse has announced an additional amendment to its 2018 agreement with Vyera Pharmaceuticals (now Phoenixus) in order for the company to repurchase 9% of royalties payable on any future net sales of SLS-002 intranasal racemic ketamine. A previous amendment to the agreement that allowed Seelos to make cash and stock payments instead of a milestone … [Read more...] about Seelos repurchases royalties on any future sales of SLS-002 intranasal racemic ketamine